Cargando…

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT00769470), participants with early-stage HER2-positive breast cancer (N = 128) were recruited from 13 United States oncol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurvitz, Sara A., Caswell-Jin, Jennifer L., McNamara, Katherine L., Zoeller, Jason J., Bean, Gregory R., Dichmann, Robert, Perez, Alejandra, Patel, Ravindranath, Zehngebot, Lee, Allen, Heather, Bosserman, Linda, DiCarlo, Brian, Kennedy, April, Giuliano, Armando, Calfa, Carmen, Molthrop, David, Mani, Aruna, Chen, Hsiao-Wang, Dering, Judy, Adams, Brad, Kotler, Eran, Press, Michael F., Brugge, Joan S., Curtis, Christina, Slamon, Dennis J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673127/ https://www.ncbi.nlm.nih.gov/pubmed/33203854 http://dx.doi.org/10.1038/s41467-020-19494-2

Ejemplares similares

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)
por: Hurvitz, Sara, et al.
Publicado: (2018)

Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy
por: Zoeller, Jason J., et al.
Publicado: (2021)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
por: Wang, Leiping, et al.
Publicado: (2011)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
por: Yang, Fan, et al.
Publicado: (2020)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
por: de Haas, Sanne L., et al.
Publicado: (2023)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01
por: Hirasawa, Makoto, et al.
Publicado: (2015)

Using DNA pools for genotyping trios
por: Beckman, Kenneth B., et al.
Publicado: (2006)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
por: OKITA, RIKI, et al.
Publicado: (2015)

Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
por: Liu, Hao, et al.
Publicado: (2023)

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
por: Hurvitz, Sara A, et al.
Publicado: (2014)

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
por: Guérin, Annie, et al.
Publicado: (2014)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
por: Ogawa, Lauren, et al.
Publicado: (2018)

Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma
por: Ye, Minfeng, et al.
Publicado: (2019)

Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
por: Xu, Zhi-qiao, et al.
Publicado: (2017)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
por: Chen, Zhe-Ling, et al.
Publicado: (2016)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
por: Eiger, Daniel, et al.
Publicado: (2020)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Trío /
por: Garibay, Ricardo
Publicado: (1993)

The trio
Publicado: (1997)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Trio. Remenbranzas
por: Dorantes, Edgar

Clair3-trio: high-performance Nanopore long-read variant calling in family trios with trio-to-trio deep neural networks
por: Su, Junhao, et al.
Publicado: (2022)

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
por: Hammerman, Ariel, et al.
Publicado: (2015)

CORRIGENDUM to “Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma”
Publicado: (2020)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Guitar trios Trios concertants, op. 18 /
por: Fossa, François de, 1775-1849
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_fv5kd9gjo68cc83t6c8r848fi4